"Octreotide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
Descriptor ID |
D015282
|
MeSH Number(s) |
D04.345.566.650 D12.644.641.650
|
Concept/Terms |
SMS 201-995- SMS 201-995
- SMS 201 995
- SMS 201995
- SM 201-995
- SM 201 995
- SM 201995
- Sandoz 201-995
- Sandoz 201 995
- Sandoz 201995
- Compound 201-995
- Compound 201 995
- Compound 201995
- SAN 201-995
- SAN 201 995
- SAN 201995
|
Below are MeSH descriptors whose meaning is more general than "Octreotide".
Below are MeSH descriptors whose meaning is more specific than "Octreotide".
This graph shows the total number of publications written about "Octreotide" by people in this website by year, and whether "Octreotide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 1 | 3 |
1995 | 3 | 0 | 3 |
1996 | 1 | 0 | 1 |
1997 | 3 | 0 | 3 |
1998 | 1 | 1 | 2 |
1999 | 1 | 0 | 1 |
2000 | 1 | 0 | 1 |
2001 | 1 | 0 | 1 |
2002 | 1 | 0 | 1 |
2003 | 0 | 2 | 2 |
2005 | 2 | 0 | 2 |
2006 | 2 | 0 | 2 |
2007 | 0 | 1 | 1 |
2008 | 2 | 3 | 5 |
2009 | 1 | 3 | 4 |
2010 | 1 | 1 | 2 |
2011 | 1 | 0 | 1 |
2012 | 1 | 1 | 2 |
2013 | 4 | 3 | 7 |
2014 | 2 | 1 | 3 |
2015 | 4 | 1 | 5 |
2016 | 2 | 0 | 2 |
2017 | 2 | 1 | 3 |
2018 | 1 | 0 | 1 |
2019 | 0 | 1 | 1 |
2020 | 1 | 2 | 3 |
2021 | 1 | 2 | 3 |
2022 | 0 | 2 | 2 |
2023 | 0 | 2 | 2 |
2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Octreotide" by people in Profiles.
-
Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clin Cancer Res. 2024 02 16; 30(4):680-686.
-
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. Trials. 2024 Jan 16; 25(1):58.
-
A radiomic- and dosiomic-based machine learning regression model for pretreatment planning in 177 Lu-DOTATATE therapy. Med Phys. 2023 Nov; 50(11):7222-7235.
-
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst. 2023 09 07; 115(9):1001-1010.
-
Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis. Ann Surg Oncol. 2022 May; 29(5):3072-3084.
-
External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy. JAMA Netw Open. 2022 01 04; 5(1):e2144170.
-
Sirolimus efficacy in the treatment of critically ill infants with congenital primary chylous effusions. Pediatr Blood Cancer. 2022 02; 69(2):e29510.
-
177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 12; 22(12):1752-1763.
-
Carcinoid Tumors of the Orbit and Ocular Adnexa. Ophthalmic Plast Reconstr Surg. 2021 May-Jun 01; 37(3):217-225.
-
A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021 Feb; 24(1):1-13.